Reported positions
Quarter-end holdings as filed
Explore the full published position list and its source filing. This record excludes the manager’s cash, shorts and non-13(f) assets.
DEERFIELD MANAGEMENT COMPANY, L.P.
A quarter-end snapshot. Filed up to 45 days later, so this page is not current holdings and never a complete portfolio. what a 13F is — and is not ↓ · methodology §13F ↗
Period
$8.5B
reported valuesum of disclosed values for 2026-03-31; 0 positions carry a NULL value and are excluded from the sum, surfaced here rather than folded away
82
positionsALL retained default holdings for this (filer, period), including NULL-value ones
12
new stakespositions with no comparable holding in the prior quarter (kind new), 2026-03-31
80
exitspositions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record
Position changes — into 2026-03-31
by shares · Δ value · filing link · how changes are classified §Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
PRAXIS PRECISION MEDICINES I COM NEWposition key pos:11991 · issuer key iss:1748 | add | +$44.1M | +60,000 | $266M | $310M | 903,351 | 963,351 | |
UNITED THERAPEUTICS CORP DEL COMposition key pos:15902 · issuer key iss:2217 | add | +$63.4M | +31,007 | $208M | $271M | 425,993 | 457,000 | |
REVOLUTION MEDICINES INC COMposition key pos:15541 · issuer key iss:1842 | trim | −$7.2M | −597,613 | $231M | $223M | 2,894,613 | 2,297,000 | |
ARROWHEAD PHARMACEUTICALS IN NOTE 1/1position key pos:12542 · issuer key iss:249 PRN | new | +$207M | +200,000,000 | $0 | $207M | — | 200,000,000 | |
CENTENE CORP DEL COMposition key pos:13554 · issuer key iss:546 | trim | −$71.6M | −530,907 | $265M | $194M | 6,447,998 | 5,917,091 | |
LARIMAR THERAPEUTICS INC COMposition key sid:sec:prov:853ca021ff04669801b685877f2dabbb · issuer key cusip6:517125 | add | +$43.6M | +5,000,000 | $117M | $160M | 30,606,974 | 35,606,974 | |
VERA THERAPEUTICS INC CL Aposition key sid:sec:prov:c6f0567aff349dfe2dab4a6ee5ba8988 · issuer key cusip6:92337R | trim | −$55.8M | −337,595 | $206M | $150M | 4,059,695 | 3,722,100 | |
BIOCRYST PHARMACEUTICALS INC COMposition key pos:15962 · issuer key iss:374 | add | +$31.3M | +697,000 | $112M | $143M | 14,341,000 | 15,038,000 | |
INSPIRE MED SYS INC COMposition key pos:14444 · issuer key iss:1183 | add | +$546K | +1,197,366 | $139M | $139M | 1,505,872 | 2,703,238 | |
LEGEND BIOTECH CORP SPONSORED ADSposition key sid:sec:prov:235b0febe313b5e3f4a7bc8d76a41721 · issuer key cusip6:52490G | add | +$10.1M | +1,755,638 | $129M | $139M | 5,932,000 | 7,687,638 | |
NEWAMSTERDAM PHARMA COMPANY ORDINARY SHARESposition key pos:17285 · issuer key iss:2704 | add | −$9.6M | +100,000 | $146M | $137M | 4,164,789 | 4,264,789 | |
ARROWHEAD PHARMACEUTICALS IN COMposition key pos:16618 · issuer key iss:249 | trim | −$23.0M | −259,649 | $122M | $98.6M | 1,832,946 | 1,573,297 | |
CATALYST PHARMACEUTICALS INC COMposition key pos:15084 · issuer key iss:535 | trim | −$17.0M | −967,561 | $115M | $97.6M | 4,911,161 | 3,943,600 | |
INDIVIOR PHARMACEUTICALS INC COMposition key pos:18425 · issuer key iss:1171 | new | +$94.4M | +3,097,790 | $0 | $94.4M | — | 3,097,790 | |
XENON PHARMACEUTICALS INC COMposition key pos:13384 · issuer key iss:2365 | add | +$69.7M | +1,073,676 | $24.3M | $94.0M | 542,020 | 1,615,696 | |
SYNDAX PHARMACEUTICALS INC COMposition key sid:sec:prov:eb359106a5c4d721cdc955ced4da0795 · issuer key cusip6:87164F | new | +$88.3M | +3,779,900 | $0 | $88.3M | — | 3,779,900 | |
TANGO THERAPEUTICS INC COMposition key pos:12388 · issuer key iss:2086 | add | +$61.0M | +1,239,867 | $25.8M | $86.8M | 2,906,946 | 4,146,813 | |
DIANTHUS THERAPEUTICS INC COMposition key pos:18462 · issuer key iss:731 | new | +$85.6M | +1,019,813 | $0 | $85.6M | — | 1,019,813 | |
PFIZER INC COMposition key pos:11636 · issuer key iss:1709 | new | +$85.4M | +3,040,000 | $0 | $85.4M | — | 3,040,000 | |
NEUROCRINE BIOSCIENCES INC COMposition key pos:12315 · issuer key iss:1552 | trim | −$87.6M | −574,345 | $168M | $80.4M | 1,184,345 | 610,000 | |
ZENAS BIOPHARMA INC NOTE 2.500% 4/0position key sid:sec:prov:9e44fcb5d06cd4275ddb0cb55c993d45 · issuer key cusip6:98937L PRN | new | +$67.3M | +65,000,000 | $0 | $67.3M | — | 65,000,000 | |
GENMAB A/S SPONSORED ADSposition key pos:17380 · issuer key iss:1001 | new | +$66.1M | +2,462,000 | $0 | $66.1M | — | 2,462,000 | |
ENVISTA HOLDINGS CORPORATION COMposition key pos:12516 · issuer key iss:835 | trim | +$6.6M | −70,398 | $49.5M | $56.1M | 2,280,498 | 2,210,100 | |
IDEAYA BIOSCIENCES INC COMposition key sid:sec:prov:f7d48a640772d3aa60939ca4949078c5 · issuer key cusip6:45166A | trim | −$23.5M | −623,035 | $74.4M | $51.0M | 2,153,043 | 1,530,008 | |
BELITE BIO INC SPONSORED ADSposition key sid:sec:prov:831c753eb8a6ce9972092ec4165601d4 · issuer key cusip6:07782B | add | +$11.1M | +70,200 | $37.4M | $48.5M | 233,813 | 304,013 | |
BIOMARIN PHARMACEUTICAL INC COMposition key pos:11882 · issuer key iss:375 | new | +$48.1M | +851,556 | $0 | $48.1M | — | 851,556 | |
DISC MEDICINE INC COMposition key pos:13022 · issuer key iss:741 | add | +$1.4M | +145,837 | $40.6M | $42.0M | 511,163 | 657,000 | |
EMBECTA CORP COMMON STOCKposition key pos:12610 · issuer key iss:808 | trim | −$10.3M | −217,070 | $32.7M | $22.4M | 2,752,031 | 2,534,961 | |
TYRA BIOSCIENCES INC COMposition key sid:sec:prov:47170149b82e95e4444c881acffa67fc · issuer key cusip6:90240B | new | +$21.0M | +549,000 | $0 | $21.0M | — | 549,000 | |
FOGHORN THERAPEUTICS INC COMposition key sid:sec:prov:d7ce1f7304a65bd9fa8becb1437c7f71 · issuer key cusip6:344174 | add | +$1.3M | +745,156 | $19.7M | $21.0M | 3,649,211 | 4,394,367 | |
BRIGHT MINDS BIOSCIENCES INC COM NEWposition key sid:sec:prov:fed138ced9737b90542a54b9484d2da0 · issuer key cusip6:10919W | new | +$20.7M | +283,000 | $0 | $20.7M | — | 283,000 | |
MONOPAR THERAPEUTICS INC COM NEWposition key sid:sec:prov:8416c67ffd3651f6a5f8d9788c0f2e31 · issuer key cusip6:61023L | add | +$6.6M | +153,187 | $11.1M | $17.7M | 170,558 | 323,745 | |
SPYGLASS PHARMA INC COM SHSposition key sid:sec:prov:04667cad8d94d5f8ff4744e87dea829b · issuer key cusip6:85220G | new | +$14.3M | +550,000 | $0 | $14.3M | — | 550,000 | |
BETA BIONICS INC COMposition key sid:sec:prov:4e7eb09ab13c64fd6730ede8dbc988b8 · issuer key cusip6:08659B | add | −$15.3M | +385,692 | $28.6M | $13.3M | 938,308 | 1,324,000 | |
BIOMX INC COM NEWposition key sid:sec:prov:33cefd366aaeacb00c6016055a143d33 · issuer key cusip6:09090D | add | +$247K | +2 | $245K | $493K | 131,270 | 131,272 | |
VERADERMICS INC COMMON STOCKposition key pos:15115 · issuer key iss:2252 | new | +$316K | +5,000 | $0 | $316K | — | 5,000 | |
| pos:11213 | exit‡e | −$2.1M | −126,574 | $2.1M | $0 | 126,574 | — | |
| pos:11309 | exit‡e | −$1.8M | −660,133 | $1.8M | $0 | 660,133 | — | |
| pos:11452 | exit‡e | −$122M | −3,393,063 | $122M | $0 | 3,393,063 | — | |
| pos:11587 | exit‡e | −$1.9M | −167,061 | $1.9M | $0 | 167,061 | — | |
| pos:11912 | exit‡e | −$3.5M | −13,825 | $3.5M | $0 | 13,825 | — | |
| pos:11965 | exit‡e | −$1.2M | −57,277 | $1.2M | $0 | 57,277 | — | |
| pos:11987 | exit‡e | −$3.6M | −49,951 | $3.6M | $0 | 49,951 | — | |
| pos:12209 | exit‡e | −$807K | −68,057 | $807K | $0 | 68,057 | — | |
| pos:12236 | exit‡e | −$859K | −25,835 | $859K | $0 | 25,835 | — | |
| pos:12237 | exit‡e | −$1.7M | −18,798 | $1.7M | $0 | 18,798 | — | |
| pos:12663 | exit‡e | −$19.0M | −765,694 | $19.0M | $0 | 765,694 | — | |
| pos:12755 | exit‡e | −$717K | −5,698 | $717K | $0 | 5,698 | — | |
| pos:12968 | exit‡e | −$1.5M | −16,231 | $1.5M | $0 | 16,231 | — | |
| pos:13005 | exit‡e | −$2.1M | −52,076 | $2.1M | $0 | 52,076 | — | |
| pos:13203 | exit‡e | −$406K | −21,259 | $406K | $0 | 21,259 | — | |
| pos:13207 | exit‡e | −$2.1M | −12,099 | $2.1M | $0 | 12,099 | — | |
| pos:13229 | exit‡e | −$1.4M | −11,449 | $1.4M | $0 | 11,449 | — | |
| pos:13299 | exit‡e | −$3.2M | −18,392 | $3.2M | $0 | 18,392 | — | |
| pos:13340 | exit‡e | −$3.4M | −127,270 | $3.4M | $0 | 127,270 | — | |
| pos:13354 PUT | exit‡e | −$29.5M | −1,000,000 | $29.5M | $0 | 1,000,000 | — | |
| pos:13464 | exit‡e | −$360K | −2,199 | $360K | $0 | 2,199 | — | |
| pos:13470 | exit‡e | −$3.2M | −164,345 | $3.2M | $0 | 164,345 | — | |
| pos:13475 | exit‡e | −$1.0M | −13,326 | $1.0M | $0 | 13,326 | — | |
| pos:13535 PRN | exit‡e | −$28.9M | −25,255,000 | $28.9M | $0 | 25,255,000 | — | |
| pos:13549 | exit‡e | −$410K | −52,230 | $410K | $0 | 52,230 | — | |
| pos:14120 | exit‡e | −$343K | −1,352 | $343K | $0 | 1,352 | — | |
| pos:14238 | exit‡e | −$4.0M | −17,711 | $4.0M | $0 | 17,711 | — | |
| pos:14500 | exit‡e | −$23.3M | −710,626 | $23.3M | $0 | 710,626 | — | |
| pos:14505 | exit‡e | −$608K | −33,987 | $608K | $0 | 33,987 | — | |
| pos:14734 | exit‡e | −$33.8M | −1,999,045 | $33.8M | $0 | 1,999,045 | — | |
| pos:14843 | exit‡e | −$1.9M | −27,629 | $1.9M | $0 | 27,629 | — | |
| pos:14860 | exit‡e | −$2.1M | −25,815 | $2.1M | $0 | 25,815 | — | |
| pos:14931 | exit‡e | −$1.7M | −11,000 | $1.7M | $0 | 11,000 | — | |
| pos:14974 | exit‡e | −$2.4M | −24,941 | $2.4M | $0 | 24,941 | — | |
| pos:15246 | exit‡e | −$2.4M | −20,909 | $2.4M | $0 | 20,909 | — | |
| pos:15356 | exit‡e | −$1.1M | −65,344 | $1.1M | $0 | 65,344 | — | |
| pos:15401 | exit‡e | −$426K | −8,693 | $426K | $0 | 8,693 | — | |
| pos:15619 | exit‡e | −$2.1M | −52,555 | $2.1M | $0 | 52,555 | — | |
| pos:15768 | exit‡e | −$1.1M | −5,098 | $1.1M | $0 | 5,098 | — | |
| pos:15817 | exit‡e | −$12.9M | −1,107,944 | $12.9M | $0 | 1,107,944 | — | |
| pos:15897 | exit‡e | −$12.9K | −733,333 | $12.9K | $0 | 733,333 | — | |
| pos:15920 | exit‡e | −$2.2M | −32,943 | $2.2M | $0 | 32,943 | — | |
| pos:15944 | exit‡e | −$2.9M | −120,211 | $2.9M | $0 | 120,211 | — | |
| pos:16108 | exit‡e | −$1.2M | −3,551 | $1.2M | $0 | 3,551 | — | |
| pos:16209 | exit‡e | −$1.8M | −8,985 | $1.8M | $0 | 8,985 | — | |
| pos:16301 | exit‡e | −$10.9M | −260,000 | $10.9M | $0 | 260,000 | — | |
| pos:16385 | exit‡e | −$2.5M | −9,203 | $2.5M | $0 | 9,203 | — | |
| pos:16392 | exit‡e | −$460K | −2,014 | $460K | $0 | 2,014 | — | |
| pos:16467 | exit‡e | −$55.0K | −166,666 | $55.0K | $0 | 166,666 | — | |
| pos:16718 | exit‡e | −$545K | −52,257 | $545K | $0 | 52,257 | — | |
| pos:16755 | exit‡e | −$27.4M | −354,000 | $27.4M | $0 | 354,000 | — | |
| pos:16978 | exit‡e | −$2.6M | −936,309 | $2.6M | $0 | 936,309 | — | |
| pos:17047 | exit‡e | −$2.5M | −66,438 | $2.5M | $0 | 66,438 | — | |
| pos:17120 | exit‡e | −$4.3M | −69,669 | $4.3M | $0 | 69,669 | — | |
| pos:17293 | exit‡e | −$2.4M | −10,104 | $2.4M | $0 | 10,104 | — | |
| pos:17299 | exit‡e | −$999K | −10,323 | $999K | $0 | 10,323 | — | |
| pos:17566 | exit‡e | −$321K | −11,996 | $321K | $0 | 11,996 | — | |
| pos:17616 | exit‡e | −$2.7M | −6,215 | $2.7M | $0 | 6,215 | — | |
| pos:17679 | exit‡e | −$1.4M | −16,606 | $1.4M | $0 | 16,606 | — | |
| pos:17695 | exit‡e | −$266K | −10,284 | $266K | $0 | 10,284 | — | |
| pos:17712 | exit‡e | −$274K | −483 | $274K | $0 | 483 | — | |
| pos:17918 | exit‡e | −$638K | −7,786 | $638K | $0 | 7,786 | — | |
| pos:18046 | exit‡e | −$2.3M | −51,942 | $2.3M | $0 | 51,942 | — | |
| pos:18144 | exit‡e | −$3.0M | −10,616 | $3.0M | $0 | 10,616 | — |
80 more changes below.
1–100 of 116 changes
Mark-to-market only (no share change) · 46
Positions whose share count is identical in both quarters; the value changed with price, not with a decision.
Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
NUVALENT INC COMposition key pos:14079 · issuer key iss:1594 | no change | +$32.1M | 0 | $1.7B | $1.8B | 17,248,450 | 17,248,450 | |
BROOKDALE SR LIVING INC NOTE 3.500%10/1position key pos:13324 · issuer key iss:443 PRN | no change | +$77.9M | 0 | $427M | $505M | 306,885,000 | 306,885,000 | |
COGENT BIOSCIENCES INC COMposition key pos:18333 · issuer key iss:610 | no change | +$26.9M | 0 | $321M | $348M | 9,043,903 | 9,043,903 | |
VIATRIS INC COMposition key pos:16938 · issuer key iss:2270 | no change | +$21.4M | 0 | $252M | $273M | 20,206,170 | 20,206,170 | |
MIRUM PHARMACEUTICALS INC NOTE 4.000% 5/0position key pos:14377 · issuer key iss:1485 PRN | no change | +$28.7M | 0 | $181M | $209M | 70,000,000 | 70,000,000 | |
CELCUITY INC COMposition key pos:11232 · issuer key iss:542 | no change | +$24.7M | 0 | $171M | $196M | 1,714,000 | 1,714,000 | |
BROOKDALE SR LIVING INC COMposition key pos:11630 · issuer key iss:443 | no change | +$33.6M | 0 | $126M | $159M | 11,637,032 | 11,637,032 | |
IONIS PHARMACEUTICALS INC COMposition key pos:12370 · issuer key iss:1221 | no change | −$8.0M | 0 | $157M | $149M | 1,979,669 | 1,979,669 | |
ADAPTHEALTH CORP COMMON STOCKposition key sid:sec:prov:426666fb8d43f8a6c202109e44eb876f · issuer key cusip6:00653Q | no change | +$22.3M | 0 | $114M | $137M | 11,477,730 | 11,477,730 | |
ACADIA HEALTHCARE COMPANY IN COMposition key pos:13278 · issuer key iss:55 | no change | +$41.6M | 0 | $64.1M | $106M | 4,520,000 | 4,520,000 | |
IONIS PHARMACEUTICALS INC NOTE 1.750% 6/1position key pos:12221 · issuer key iss:1221 PRN | no change | −$4.7M | 0 | $95.3M | $90.6M | 60,000,000 | 60,000,000 | |
PHARVARIS N V COMposition key pos:15462 · issuer key iss:2706 | no change | +$1.6M | 0 | $86.7M | $88.3M | 3,126,042 | 3,126,042 | |
ALIGNMENT HEALTHCARE INC NOTE 4.250%11/1position key pos:14636 · issuer key iss:135 PRN | no change | −$6.7M | 0 | $92.6M | $85.9M | 61,000,000 | 61,000,000 | |
DAY ONE BIOPHARMACEUTICALS I COMposition key sid:sec:prov:5fa73bae4b4007f19790df8489a7fcc7 · issuer key cusip6:23954D | no change | +$45.1M | 0 | $34.7M | $79.8M | 3,723,131 | 3,723,131 | |
SAVARA INC COMposition key sid:sec:prov:2bc6a25d40cf07124e3a03bdecf4a4df · issuer key cusip6:805111 | no change | −$7.7M | 0 | $81.8M | $74.1M | 13,569,000 | 13,569,000 | |
ENHABIT INC COMposition key sid:sec:prov:7bf659316464fda9fc46729d980abb67 · issuer key cusip6:29332G | no change | +$23.1M | 0 | $43.8M | $66.9M | 4,747,746 | 4,747,746 | |
NEOGENOMICS INC NOTE 0.250% 1/1position key pos:14768 · issuer key iss:1542 PRN | no change | +$2.0M | 0 | $64.7M | $66.7M | 72,689,000 | 72,689,000 | |
BIO RAD LABS INC CL Aposition key pos:14841 · issuer key iss:373 | no change | −$5.5M | 0 | $68.5M | $63.0M | 226,070 | 226,070 | |
LANTHEUS HLDGS INC COMposition key pos:14656 · issuer key iss:1326 | no change | +$7.7M | 0 | $55.1M | $62.8M | 827,999 | 827,999 | |
ARS PHARMACEUTICALS INC COMposition key pos:11241 · issuer key iss:1972 | no change | −$27.2M | 0 | $87.4M | $60.3M | 7,503,812 | 7,503,812 | |
STOKE THERAPEUTICS INC COMposition key sid:sec:prov:3fee4169345e05a49cf14bcc2babfc71 · issuer key cusip6:86150R | no change | +$1.5M | 0 | $57.9M | $59.4M | 1,823,500 | 1,823,500 | |
KYMERA THERAPEUTICS INC COMposition key pos:13465 · issuer key iss:1310 | no change | +$3.1M | 0 | $43.7M | $46.7M | 561,170 | 561,170 | |
CERTARA INC COMposition key pos:15467 · issuer key iss:557 | no change | −$24.3M | 0 | $68.8M | $44.5M | 7,808,605 | 7,808,605 | |
BRIDGEBIO ONCOLOGY THERAPEUT COM NEWposition key pos:12931 · issuer key iss:426 | no change | −$17.4M | 0 | $61.2M | $43.7M | 4,885,446 | 4,885,446 | |
LIVANOVA PLC NOTE 2.500% 3/1position key sid:sec:prov:e40e4bba291a4c5e0e2b5429181fff16 · issuer key cusip6:53802L PRN | no change | +$308K | 0 | $39.7M | $40.0M | 34,280,000 | 34,280,000 | |
SIONNA THERAPEUTICS INC COMposition key pos:11054 · issuer key iss:1980 | no change | −$1.0M | 0 | $39.9M | $38.9M | 970,590 | 970,590 | |
CAREDX INC COMposition key pos:13317 · issuer key iss:517 | no change | −$3.2M | 0 | $41.3M | $38.0M | 2,191,000 | 2,191,000 | |
STRUCTURE THERAPEUTICS INC SPONSORED ADSposition key sid:sec:prov:862b191ccb923fc424f39385b48ce4f8 · issuer key cusip6:86366E | no change | −$16.4M | 0 | $53.4M | $37.0M | 767,993 | 767,993 | |
IMMUNOCORE HLDGS PLC NOTE 2.500% 2/0position key pos:18629 · issuer key iss:1166 PRN | no change | −$56.7K | 0 | $27.1M | $27.0M | 30,000,000 | 30,000,000 | |
VERACYTE INC COMposition key pos:15789 · issuer key iss:2254 | no change | −$7.2M | 0 | $30.6M | $23.4M | 726,000 | 726,000 | |
ALNYLAM PHARMACEUTICALS INC COMposition key pos:16018 · issuer key iss:150 | no change | −$4.5M | 0 | $27.0M | $22.5M | 67,935 | 67,935 | |
COMPASS THERAPEUTICS INC COMposition key sid:sec:prov:c5f3f37de4d48fd1b29c266e9a76eb0b · issuer key cusip6:20454B | no change | −$288K | 0 | $19.4M | $19.1M | 3,606,000 | 3,606,000 | |
KYVERNA THERAPEUTICS INC COMposition key sid:sec:prov:025f5bfc45d0f21f39b99aeb6192bfc1 · issuer key cusip6:501976 | no change | −$1.5M | 0 | $18.8M | $17.3M | 2,000,000 | 2,000,000 | |
TAYSHA GENE THERAPIES INC COM SHSposition key pos:14669 · issuer key iss:2095 | no change | −$2.8M | 0 | $15.0M | $12.2M | 2,722,165 | 2,722,165 | |
THE ONCOLOGY INSTITUTE INC COMposition key pos:17032 · issuer key iss:1622 | no change | −$1.6M | 0 | $12.0M | $10.3M | 3,360,052 | 3,360,052 | |
CULLINAN THERAPEUTICS INC COMposition key pos:13492 · issuer key iss:693 | no change | +$1.5M | 0 | $4.0M | $5.5M | 386,169 | 386,169 | |
ANNEXON INC COMposition key sid:sec:prov:45f58e3bf467aafd3516eb30bc85b601 · issuer key cusip6:03589W | no change | +$304K | 0 | $2.9M | $3.2M | 583,913 | 583,913 | |
ALECTOR INC COMposition key sid:sec:prov:1c7c81831d7de024bffc2474a53ee4b9 · issuer key cusip6:014442 | no change | +$623K | 0 | $1.6M | $2.3M | 1,055,192 | 1,055,192 | |
NEWAMSTERDAM PHARMA COMPANY *W EXP 99/99/999position key pos:14719 · issuer key iss:2704 | no change | −$275K | 0 | $2.1M | $1.9M | 92,787 | 92,787 | |
EDWARDS LIFESCIENCES CORP COMposition key pos:17342 · issuer key iss:799 | no change | −$70.8K | 0 | $1.2M | $1.1M | 13,702 | 13,702 | |
HUMANA INC COMposition key pos:11393 · issuer key iss:1136 | no change | −$75.9K | 0 | $235K | $159K | 917 | 917 | |
THE ONCOLOGY INSTITUTE INC *W EXP 99/99/999position key pos:12171 · issuer key iss:1622 | no change | −$95.9K | 0 | $151K | $54.8K | 1,250,000 | 1,250,000 | |
QUANTUM SI INC *W EXP 06/10/202position key sid:sec:prov:caf6739f474e5aab1341e36d2fc446d1 · issuer key cusip6:74765K | no change | −$30.6K | 0 | $66.8K | $36.2K | 333,333 | 333,333 | |
PMV PHARMACEUTICALS INC COMposition key sid:sec:prov:325eed3e19d59a984be6eb2201e2d894 · issuer key cusip6:69353Y | no change | −$88 | 0 | $11.0K | $10.9K | 8,790 | 8,790 | |
SURROZEN INC *W EXP 08/01/203position key sid:sec:prov:c4f97db1890f36f80c7a359d19822318 · issuer key cusip6:86889P | no change | −$666 | 0 | $3.3K | $2.7K | 166,666 | 166,666 | |
MYRIAD GENETICS INC COMposition key pos:16125 · issuer key iss:1518 | no change | −$833 | 0 | $3.1K | $2.3K | 505 | 505 |
Quarter ended 2026-03-31Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.
Changes derive from the aggregate's top-25 slices and keyable positions only; unkeyable holdings are counted in the registry, not differenced. methodology §13F ↗
Book shape
2026-03-31 · concentration · vs tracked median · tick = median- Top-25 concentration
- 74.4%below median 80.0%
- Concentration index
- 602 bpsabove median 446 bps
- Positions with value
- 82 / 82median book 97.5 positions
Concentration uses reported 13F long value, not total assets. The index is withheld when any position lacks a value. Medians are over the 8,748 tracked filers with a 2026-03-31 book; the index median over the 8,662 with a complete book.
null-value positions: 0holdings whose <value> did not parse — retained and counted, never zero-filled · top-N share ·§: 74.4% · HHI (bps) ·§: 602integer Herfindahl–Hirschman index in basis points over disclosed position values · QoQ moves: 162
Filing history
AVAILABLE QUARTERS| Period | Source |
|---|---|
| 2026-03-31 | EDGAR ↗ |
PLANNED sector rotation · Congress overlap · signals for this filer
Complete source filings on SEC EDGAR
The complete filing on EDGAR.
The position list above is served from the published Public Filings build — every position this filer reported for the selected quarter, as it reported it. This block is provenance, not a substitute: the filing itself is the record, and it is one click away. Serving this list is M2-CONTRACT §3, amended 2026-08-02; §3.1 keeps live EDGAR for filings newer than this build.
Open DEERFIELD MANAGEMENT COMPANY, L.P.'s 13F filings on SEC EDGAR ↗Notes on this data
Share changes
Compare consecutive quarters
Position changes retain the producer’s classification and comparability flags. Share counts and reported values describe different changes.
Coverage
A snapshot, not current holdings
Use the quarter selector to inspect available periods. Unknown values stay unknown and each table states its coverage.
ViewPrior quarter not yet availableThis build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.
Reported positions — 2026-03-31
1–77 of 77 issuers · $8.5B disclosed value over 82 rows · 0 undisclosed-value rowsEvery row below carries ticker not yet mapped — stated once here rather than repeated on every row.
| KindClassification is not joined into this reported-position view. Use the changed-positions view to compare the two published quarters. | TickerThis list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names. | Issuera position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing | WeightShare of total reported value, calculated only when the full position list has disclosed values. This is 13F long value, not total assets. | Valuevalue undisclosed on the filing: retained and counted, excluded from sums, never shown as $0 | Shares | Position changeShare change is available in the separate comparison view; it is not joined into this position list. | Wt | CongressThe congressional transaction join is unavailable in this build. |
|---|---|---|---|---|---|---|---|---|
| — | NUVLverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NUVALENT INC NUVALENT INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.8B | 17,248,450 | — | 20.8% | — | |
| — | BKDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BROOKDALE SR LIVING INC | $665M | — | — | 7.8% | — | |
| — | COGTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | COGENT BIOSCIENCES INC COGENT BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $348M | 9,043,903 | — | 4.1% | — | |
| — | PRAXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PRAXIS PRECISION MEDICINES I PRAXIS PRECISION MEDICINES I · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $310M | 963,351 | — | 3.7% | — | |
| — | ARWRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ARROWHEAD PHARMACEUTICALS IN | $306M | — | — | 3.6% | — | |
| — | VTRSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VIATRIS INC VIATRIS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $273M | 20,206,170 | — | 3.2% | — | |
| — | UTHRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | UNITED THERAPEUTICS CORP DEL UNITED THERAPEUTICS CORP DEL · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $271M | 457,000 | — | 3.2% | — | |
| — | IONSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IONIS PHARMACEUTICALS INC | $239M | — | — | 2.8% | — | |
| — | RVMDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | REVOLUTION MEDICINES INC REVOLUTION MEDICINES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $223M | 2,297,000 | — | 2.6% | — | |
| — | — | MIRUM PHARMACEUTICALS INC MIRUM PHARMACEUTICALS INC · NOTE 4.000% 5/0 CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $209M | 70,000,000 PRN | — | 2.5% | — | |
| — | CELCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CELCUITY INC CELCUITY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $196M | 1,714,000 | — | 2.3% | — | |
| — | CNCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CENTENE CORP DEL CENTENE CORP DEL · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $194M | 5,917,091 | — | 2.3% | — | |
| — | — | LARIMAR THERAPEUTICS INC LARIMAR THERAPEUTICS INC · COM CUSIP 517125100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $160M | 35,606,974 | — | 1.9% | — | |
| — | — | VERA THERAPEUTICS INC VERA THERAPEUTICS INC · CL A CUSIP 92337R101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $150M | 3,722,100 | — | 1.8% | — | |
| — | BCRXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BIOCRYST PHARMACEUTICALS INC BIOCRYST PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $143M | 15,038,000 | — | 1.7% | — | |
| — | INSPverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INSPIRE MED SYS INC INSPIRE MED SYS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $139M | 2,703,238 | — | 1.6% | — | |
| — | — | LEGEND BIOTECH CORP LEGEND BIOTECH CORP · SPONSORED ADS CUSIP 52490G102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $139M | 7,687,638 | — | 1.6% | — | |
| — | NAMSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NEWAMSTERDAM PHARMA COMPANY | $138M | 4,357,576 | — | 1.6% | — | |
| — | — | ADAPTHEALTH CORP ADAPTHEALTH CORP · COMMON STOCK CUSIP 00653Q102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $137M | 11,477,730 | — | 1.6% | — | |
| — | ACHCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ACADIA HEALTHCARE COMPANY IN ACADIA HEALTHCARE COMPANY IN · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $106M | 4,520,000 | — | 1.2% | — | |
| — | CPRXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CATALYST PHARMACEUTICALS INC CATALYST PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $97.6M | 3,943,600 | — | 1.2% | — | |
| — | INDVverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INDIVIOR PHARMACEUTICALS INC INDIVIOR PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $94.4M | 3,097,790 | — | 1.1% | — | |
| — | XENEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | XENON PHARMACEUTICALS INC XENON PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $94.0M | 1,615,696 | — | 1.1% | — | |
| — | PHVSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PHARVARIS N V PHARVARIS N V · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $88.3M | 3,126,042 | — | 1.0% | — | |
| — | — | SYNDAX PHARMACEUTICALS INC SYNDAX PHARMACEUTICALS INC · COM CUSIP 87164F105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $88.3M | 3,779,900 | — | 1.0% | — | |
| — | TNGXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TANGO THERAPEUTICS INC TANGO THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $86.8M | 4,146,813 | — | 1.0% | — | |
| — | — | ALIGNMENT HEALTHCARE INC ALIGNMENT HEALTHCARE INC · NOTE 4.250%11/1 CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $85.9M | 61,000,000 PRN | — | 1.0% | — | |
| — | DNTHverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DIANTHUS THERAPEUTICS INC DIANTHUS THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $85.6M | 1,019,813 | — | 1.0% | — | |
| — | PFEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PFIZER INC PFIZER INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $85.4M | 3,040,000 | — | 1.0% | — | |
| — | NBIXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NEUROCRINE BIOSCIENCES INC NEUROCRINE BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $80.4M | 610,000 | — | 0.9% | — | |
| — | — | DAY ONE BIOPHARMACEUTICALS I DAY ONE BIOPHARMACEUTICALS I · COM CUSIP 23954D109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $79.8M | 3,723,131 | — | 0.9% | — | |
| — | — | SAVARA INC SAVARA INC · COM CUSIP 805111101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $74.1M | 13,569,000 | — | 0.9% | — | |
| — | — | ZENAS BIOPHARMA INC ZENAS BIOPHARMA INC · NOTE 2.500% 4/0 CUSIP 98937LAA3 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $67.3M | 65,000,000 PRN | — | 0.8% | — | |
| — | — | ENHABIT INC ENHABIT INC · COM CUSIP 29332G102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $66.9M | 4,747,746 | — | 0.8% | — | |
| — | — | NEOGENOMICS INC NEOGENOMICS INC · NOTE 0.250% 1/1 CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $66.7M | 72,689,000 PRN | — | 0.8% | — | |
| — | GMABverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GENMAB A/S GENMAB A/S · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $66.1M | 2,462,000 | — | 0.8% | — | |
| — | BIOverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BIO RAD LABS INC BIO RAD LABS INC · CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $63.0M | 226,070 | — | 0.7% | — | |
| — | LNTHverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | LANTHEUS HLDGS INC LANTHEUS HLDGS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $62.8M | 827,999 | — | 0.7% | — | |
| — | SPRYverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ARS PHARMACEUTICALS INC ARS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $60.3M | 7,503,812 | — | 0.7% | — | |
| — | — | STOKE THERAPEUTICS INC STOKE THERAPEUTICS INC · COM CUSIP 86150R107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $59.4M | 1,823,500 | — | 0.7% | — | |
| — | NVSTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ENVISTA HOLDINGS CORPORATION ENVISTA HOLDINGS CORPORATION · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $56.1M | 2,210,100 | — | 0.7% | — | |
| — | — | IDEAYA BIOSCIENCES INC IDEAYA BIOSCIENCES INC · COM CUSIP 45166A102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $51.0M | 1,530,008 | — | 0.6% | — | |
| — | — | BELITE BIO INC BELITE BIO INC · SPONSORED ADS CUSIP 07782B104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $48.5M | 304,013 | — | 0.6% | — | |
| — | BMRNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BIOMARIN PHARMACEUTICAL INC BIOMARIN PHARMACEUTICAL INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $48.1M | 851,556 | — | 0.6% | — | |
| — | KYMRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | KYMERA THERAPEUTICS INC KYMERA THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $46.7M | 561,170 | — | 0.6% | — | |
| — | CERTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CERTARA INC CERTARA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $44.5M | 7,808,605 | — | 0.5% | — | |
| — | BBOTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BRIDGEBIO ONCOLOGY THERAPEUT BRIDGEBIO ONCOLOGY THERAPEUT · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $43.7M | 4,885,446 | — | 0.5% | — | |
| — | IRONverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DISC MEDICINE INC DISC MEDICINE INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $42.0M | 657,000 | — | 0.5% | — | |
| — | — | LIVANOVA PLC LIVANOVA PLC · NOTE 2.500% 3/1 CUSIP 53802LAB8 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $40.0M | 34,280,000 PRN | — | 0.5% | — | |
| — | SIONverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | SIONNA THERAPEUTICS INC SIONNA THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $38.9M | 970,590 | — | 0.5% | — | |
| — | CDNAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CAREDX INC CAREDX INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $38.0M | 2,191,000 | — | 0.4% | — | |
| — | — | STRUCTURE THERAPEUTICS INC STRUCTURE THERAPEUTICS INC · SPONSORED ADS CUSIP 86366E106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $37.0M | 767,993 | — | 0.4% | — | |
| — | — | IMMUNOCORE HLDGS PLC IMMUNOCORE HLDGS PLC · NOTE 2.500% 2/0 CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $27.0M | 30,000,000 PRN | — | 0.3% | — | |
| — | VCYTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VERACYTE INC VERACYTE INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $23.4M | 726,000 | — | 0.3% | — | |
| — | ALNYverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ALNYLAM PHARMACEUTICALS INC ALNYLAM PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $22.5M | 67,935 | — | 0.3% | — | |
| — | EMBCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | EMBECTA CORP EMBECTA CORP · COMMON STOCK CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $22.4M | 2,534,961 | — | 0.3% | — | |
| — | — | TYRA BIOSCIENCES INC TYRA BIOSCIENCES INC · COM CUSIP 90240B106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $21.0M | 549,000 | — | 0.2% | — | |
| — | — | FOGHORN THERAPEUTICS INC FOGHORN THERAPEUTICS INC · COM CUSIP 344174107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $21.0M | 4,394,367 | — | 0.2% | — | |
| — | — | BRIGHT MINDS BIOSCIENCES INC BRIGHT MINDS BIOSCIENCES INC · COM NEW CUSIP 10919W405 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $20.7M | 283,000 | — | 0.2% | — | |
| — | — | COMPASS THERAPEUTICS INC COMPASS THERAPEUTICS INC · COM CUSIP 20454B104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $19.1M | 3,606,000 | — | 0.2% | — | |
| — | — | MONOPAR THERAPEUTICS INC MONOPAR THERAPEUTICS INC · COM NEW CUSIP 61023L207 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.7M | 323,745 | — | 0.2% | — | |
| — | — | KYVERNA THERAPEUTICS INC KYVERNA THERAPEUTICS INC · COM CUSIP 501976104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.3M | 2,000,000 | — | 0.2% | — | |
| — | — | SPYGLASS PHARMA INC SPYGLASS PHARMA INC · COM SHS CUSIP 85220G109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.3M | 550,000 | — | 0.2% | — | |
| — | — | BETA BIONICS INC BETA BIONICS INC · COM CUSIP 08659B102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.3M | 1,324,000 | — | 0.2% | — | |
| — | TSHAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TAYSHA GENE THERAPIES INC TAYSHA GENE THERAPIES INC · COM SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $12.2M | 2,722,165 | — | 0.1% | — | |
| — | — | THE ONCOLOGY INSTITUTE INC | $10.4M | 4,610,052 | — | 0.1% | — | |
| — | CGEMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CULLINAN THERAPEUTICS INC CULLINAN THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.5M | 386,169 | — | 0.1% | — | |
| — | — | ANNEXON INC ANNEXON INC · COM CUSIP 03589W102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.2M | 583,913 | — | 0.0% | — | |
| — | — | ALECTOR INC ALECTOR INC · COM CUSIP 014442107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.3M | 1,055,192 | — | 0.0% | — | |
| — | EWverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | EDWARDS LIFESCIENCES CORP EDWARDS LIFESCIENCES CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $1.1M | 13,702 | — | 0.0% | — | |
| — | — | BIOMX INC BIOMX INC · COM NEW CUSIP 09090D509 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $493K | 131,272 | — | 0.0% | — | |
| — | MANEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VERADERMICS INC VERADERMICS INC · COMMON STOCK CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $316K | 5,000 | — | 0.0% | — | |
| — | HUMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | HUMANA INC HUMANA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $159K | 917 | — | 0.0% | — | |
| — | — | QUANTUM SI INC QUANTUM SI INC · *W EXP 06/10/202 CUSIP 74765K113 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $36.2K | 333,333 | — | 0.0% | — | |
| — | — | PMV PHARMACEUTICALS INC PMV PHARMACEUTICALS INC · COM CUSIP 69353Y103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.9K | 8,790 | — | 0.0% | — | |
| — | — | SURROZEN INC SURROZEN INC · *W EXP 08/01/203 CUSIP 86889P117 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.7K | 166,666 | — | 0.0% | — | |
| — | MYGNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | MYRIAD GENETICS INC MYRIAD GENETICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.3K | 505 | — | 0.0% | — |
1–77 of 77 issuers · page 1 of 1
every row this filer reported for the quarter, as it reported it — cross-filer de-duplication is applied to issuer totals elsewhere and never deletes a row here
A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗
13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.
Positions are quarter-end snapshots filed up to 45 days late — not current holdings. A position may have been changed or closed before you ever see it, and is older still by however long ago that quarter ended.
Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars with unit_basis carried on every record.
Affiliated managers may report the same position (otherManager), so one position can appear under more than one filer.
Positions under confidential treatment may be omitted until a later amendment discloses them.
These are disclosures, not investment advice (ARCHITECTURE.md §5.2 / M2-CONTRACT §5).